Malignant melanoma: current state of primary and adjuvant treatment (Q35084330)

6 August 2017

1 reference

title

Malignant melanoma: current state of primary and adjuvant treatment (English)

1 reference

6 August 2017

1

Timothy M Pawlik

1 reference

6 August 2017

2

Vernon K Sondak

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Critical Reviews in Oncology Hematology

6 August 2017

published in

1 reference

6 August 2017

volume

45

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

245-264

1 reference

6 August 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant therapy for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Relationship of melanoma and other skin cancer mortality to latitude and ultraviolet radiation in the United States and Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Impact of clinical trials on the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A new American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

The role of elective lymph node dissection in melanoma: rationale, results, and controversies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

"Prophylactic" lymph node dissection in melanoma: does it help?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Technical details of intraoperative lymphatic mapping for early stage melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

The orderly progression of melanoma nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Evolution of sentinel lymph node biopsy for melanoma at a National Cancer Institute-designated cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Pathologic examination of the sentinel lymph node in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Reliability of sentinel lymph node biopsy for staging melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Overview analysis of adjuvant therapies for melanoma--a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant Immunotherapy with BCG in Treatment of Regional-Lymph-Node Metastases from Malignant Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant Therapy for Malignant Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Surgical adjuvant therapy for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Randomized controlled trial of transfer factor in stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant chemotherapy of malignant melanoma. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant chemoimmunotherapy stage I/II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant Treatment in Stage I and II Malignant Melanoma: A Randomized Trial between Chemoimmunotherapy and Immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

The determination of an immunologically active dose of interferon-gamma in patients with melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Rationale for recombinant human interferon-gamma adjuvant immunotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Results of adjuvant interferon study in WHO melanoma programme

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Interferons in melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Controlled trial of active immunotherapy in management of stage IIB malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Active immunotherapy in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant immunotherapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Treatment of human melanoma with a hapten-modified autologous vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Effect of DETOX as an adjuvant for melanoma vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Antiantiidiotypic Response and Clinical Course of the Disease in Patients with Malignant Melanoma Immunized with Mouse Antiidiotypic Monoclonal Antibody MK2-23

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

H-2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

1 reference

7 January 2021

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. A randomized, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

Adjuvant radiation after lymph node dissection for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2802%2900080-X

7 January 2021

10.1016/S1040-8428(02)00080-X

Identifiers

DOI

1 reference

6 August 2017

1 reference